-

Shareholder Alert: Robbins LLP is Investigating the Officers and Directors of iRobot Corp. (IRBT)

SAN DIEGO & BEDFORD, Mass.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of iRobot Corp. (NASDAQ: IRBT) breached their fiduciary duties between November 21, 2016 and the present. iRobot designs, builds, and sells robots for the consumer market worldwide.

If you suffered a loss as a result of iRobot's misconduct, click here.

iRobot Corp. (IRBT) Accused of Channel-Stuffing

Following iRobot's acquisition of two major industry distributors, iRobot reported explosive, double-digit revenue growth, with its officers and directors attributing its strong performance to growing demand for the Roomba line of products, expanded gross margin, and technological innovation. iRobot's revenue may have actually been the result of the Company's channel-stuffing to artificially boost its sales and revenue numbers. On April 23, 2019, the Company announced shockingly disappointing quarterly revenue results below analyst expectations and surging inventory levels. Then, on July 23, 2019, the Company drastically slashed its full-year earnings forecast. Finally, on October 22, 2019, iRobot cut its high end of its revenue expectations for the year, rolled back price increases due to a "suboptimal" customer response, and increased inventory levels yet again. Following these disclosures, iRobot's stock price fell a total of $81.51, or 62%, to close at $49.06.

iRobot Corp. (IRBT) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins Arroyo LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:IRBT

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins Arroyo LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom